These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1014 related items for PubMed ID: 30704287

  • 1. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
    Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM.
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.
    Chi G, Yee MK, Kalayci A, Kerneis M, AlKhalfan F, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM.
    J Thromb Thrombolysis; 2018 Oct; 46(3):346-350. PubMed ID: 29943350
    [Abstract] [Full Text] [Related]

  • 5. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
    Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K.
    Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
    [Abstract] [Full Text] [Related]

  • 6. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
    Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA.
    N Engl J Med; 2016 Dec 22; 375(25):2423-2434. PubMed ID: 27959713
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, Aronson R, Windecker S, Mehran R, Lopes RD.
    Circulation; 2020 May 19; 141(20):1618-1627. PubMed ID: 32223444
    [Abstract] [Full Text] [Related]

  • 11. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial.
    Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP.
    Circ Cardiovasc Interv; 2020 Apr 19; 13(4):e008349. PubMed ID: 32252548
    [Abstract] [Full Text] [Related]

  • 12. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP, RE-DUAL PCI Steering Committee and Investigators.
    JACC Cardiovasc Interv; 2019 Dec 09; 12(23):2331-2341. PubMed ID: 31806214
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
    Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM, ROCKET AF Steering Committee & Investigators, ROCKET AF Steering Committee Investigators.
    J Am Heart Assoc; 2016 Mar 08; 5(3):e002197. PubMed ID: 26955859
    [Abstract] [Full Text] [Related]

  • 17. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
    Desai A, Escamilla-Ocanas C, Dilip D, Saber H, Damani R.
    J Stroke Cerebrovasc Dis; 2021 Apr 08; 30(4):105654. PubMed ID: 33578352
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study.
    Yasuda S, Kaikita K, Ogawa H, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K.
    Int J Cardiol; 2018 Aug 15; 265():108-112. PubMed ID: 29764706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.